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Abstract
A draft addendum to ICH E9 has been released for public consultation in Au-
gust 2017. The addendum focuses on two topics particularly relevant for random-
ized confirmatory clinical trials: estimands and sensitivity analyses. The need to
amend ICH E9 grew out of the realization of a lack of alignment between the objec-
tives of a clinical trial stated in the protocol and the accompanying quantification
of the “treatment effect” reported in a regulatory submission. We embed time-to-
event endpoints in the estimand framework, and discuss how the four estimand
attributes described in the addendum apply to time-to-event endpoints. We point
out that if the proportional hazards assumption is not met, the estimand targeted
by the most prevalent methods used to analyze time-to-event endpoints, logrank
test and Cox regression, depends on the censoring distribution. We discuss for
a large randomized clinical trial how the analyses for the primary and secondary
endpoints as well as the sensitivity analyses actually performed in the trial can be
seen in the context of the addendum. To the best of our knowledge, this is the first
attempt to do so for a trial with a time-to-event endpoint. Questions that remain
open with the addendum for time-to-event endpoints and beyond are formulated,
and recommendations for planning of future trials are given. We hope that this
will provide a contribution to developing a common framework based on the fi-
nal version of the addendum that can be applied to design, protocols, statistical
analysis plans, and clinical study reports in the future.
Keywords: Estimand; Time-to-Event; Sensitivity Analysis; Censoring; Randomized
Clinical Trial; Causal Inference
1 Introduction
When evaluating interventions in clinical trials, time-to-event (T2E) endpoints such as
overall survival (OS) or time to a severe cardiovascular event play a prominent role.
∗Methods, Collaboration, and Outreach Group (MCO), Department of Biostatistics, Hoffmann-La
Roche Ltd, Basel, Switzerland
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Such endpoints are defined as the time between two clearly defined events, e.g. from
registration into a trial or randomisation to the earliest of (a subset of) death, appearance
of tumor, development of some disease, recurrence of a disease, and so forth. T2E
endpoints are commonly used in many indications, e.g. oncology [1], Alzheimer’s and
Parkinson’s [2], multiple sclerosis [3], or cardiovascular diseases [4].
The appearance of new types of treatments and the multiplication of lines of treatment,
especially in oncology, have resulted in the use of surrogate endpoints for OS such as
progression-free (PFS), or disease-free survival (DFS). Their development is strongly
influenced by the necessity of reducing clinical trial duration, cost and number of pa-
tients [5]. However, while these endpoints are frequently used, there is consensus in the
literature ([6], [7], [8] [5]), persistent over time, that these endpoints are often poorly
defined and definitions can differ between trials. For example, Mathoulin-Pelissier et
al. [8] found that about half of articles they reviewed, and which were published in
major clinical journals, failed to provide a clear definition of the T2E endpoint, and
68% reported insufficient information on the survival analysis.
In 2014, the Steering Committee of the International Conference on Harmonization
(ICH) endorsed the formation of an expert working group to develop an addendum
to the ICH E9 guideline (Statistical Principles for Clinical Trials) [9]. This ICH E9
draft addendum ([10], henceforth simply referred to as “addendum”) has been released
for public consultation in August 2017. It focuses on two topics particularly relevant
for confirmatory randomized clinical trials (RCT): estimands and sensitivity analyses.
According to the addendum, an estimand describes what is to be estimated based on
the question of interest and can be defined through the population of interest, endpoint
of interest, specification of how intercurrent events are handled, and summary measure.
In what follows, we refer to the specification of how intercurrent events are handled as
intervention effect. A sensitivity analysis “...can help to investigate and understand the
robustness of estimates; the sensitivity of the overall conclusions to various limitations
of the data, assumptions, and approaches to data analysis.” [11].
The need to amend E9 with a discussion on estimands grew out of the realization of an
apparent lack of alignment between the objectives stated in a clinical trial protocol and
the accompanying quantification and interpretation of the “treatment effect” reported in
a regulatory submission. While the estimand framework has been developed with differ-
ent clinical trial settings and endpoints in mind, the examples discussed in publications,
at scientific meetings, and in the addendum have largely focused on symptomatic stud-
ies and continuous, longitudinal endpoints ([12], [13], [9]). Given the realization of lack
of common definition for T2E endpoints, and the introduction of the estimand concept
in the addendum, we would like to connect these two aspects and discuss estimand
considerations as they apply to outcome trials that focus on T2E endpoints. We hope
that this, together with further efforts discussed in Section 5, will lead to alignment in
endpoint, and ultimately, estimand definitions.
While this paper was under review, Unkel et al. [14] have also looked into estimands for
T2E endpoints, as they apply to safety analyses with different follow-up times in treat-
ment arms. This illustrates that considerations for T2E endpoints within the estimand
framework do not only apply to efficacy, but also safety or quality-of-life T2E endpoints.
The key messages we want to convey in this paper are:
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• Embed T2E endpoints in the estimand framework.
• Illustrate that censoring should be considered part of the estimator (not estimand)
definition.
• We discuss the (often implicit) assumptions made when censoring at an intercur-
rent event. The decision on how an estimator deals with an intercurrent event,
e.g. whether it censors it or not, should be derived from the estimand which in
turn has to be defined first.
• If we have non-proportional hazards (NPH) and censoring, the estimand that is
estimated by the hazard ratio from Cox regression depends on the censoring dis-
tribution. This is a rather undesirable feature and we raise the question whether,
within the estimand framework, the Cox regression hazard ratio should remain
the method of choice to quantify a treatment effect for T2E endpoints. We discuss
some potential alternatives.
• Related to this, we raise the question whether hypothesis testing and effect esti-
mation need to be tied to the same estimand, or whether these can be considered
separately.
• Based on several examples from the literature, we illustrate that seemingly clearly
defined endpoints in clinical trials are subject to substantial heterogeneity in how
they are specified. We anticipate that the estimand framework will help aligning
these definitions.
• We retrospectively embed the analysis specification of a large Phase 3 oncology
RCT into the estimand framework. We hope this can serve as a basis for trial teams
to specify estimands moving forward and to inform data collection strategies.
• The addendum uses causal inference language and concepts, e.g. the principal
strata strategy. However, it is not clear whether post-addendum estimands need
to be causally interpretable. We would welcome clarification of this aspect in the
final version of the addendum.
The paper is structured as follows: In Section 2 we review the estimand attributes pro-
posed in the addendum and how they apply to T2E endpoints while Section 3 briefly
summarizes how we see the role of censoring within the estimand definition. The con-
nection between logrank test, Cox proportional hazards regression (CPHR), and the
proportional hazards (PH) assumption, especially if the latter is not met, is discussed
in Section 4. Section 5 is devoted to a brief review of examples from the literature that
illustrate how heterogeneous seemingly “clearly defined” endpoints actually are between
trials and the implications of this heterogeneity. In Section 6 we illustrate how intercur-
rent events can play a different role and thus necessitate a different estimand strategy
depending on the indication the trial is run in. As an illustration, the endpoints and
sensitivity analyses (“sensitivity” with the pre-ICH E9 addendum meaning) of a large
Phase 3 oncology trial, that has recently been reported, are then discussed in view of
the new estimand framework in Section 7. We conclude with a discussion in Section 8.
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2 Estimand attributes for T2E endpoints
In order to provide a framework for the following sections we discuss how T2E endpoints
can be viewed in the estimand framework. According to the addendum, an estimand
describes what is to be estimated based on the question of interest and can be defined
through the population, variable, intervention effect, and summary measure. Among
these, the intervention effect, which specifies how intercurrent events are reflected in the
scientific question, may be considered the attribute that in general adds most novelty
to the way how we describe trial objectives. Intercurrent events are clinical events
that occur between randomisation and before the endpoint, such as non-adherence,
discontinuation of intervention, study withdrawal, treatment switching, use of rescue
medication, second line treatment, transplantation, or death. The summary measure
specifies the quantity on which the treatment comparison will be based.
Note that the four attributes of an estimand as described in the addendum should not
be considered independently, but in relation to each other ([10], Section A.3.1). In what
follows, we discuss them as they apply to a T2E endpoint.
2.1 Population
The population to be sampled from when generating clinical trial data is usually char-
acterized through a comprehensive list of in- and exclusion criteria. We do not identify
anything specific to T2E endpoints concerning the definition of the population under
study. However, as mentioned by a reviewer, the rate of intercurrent events in the
population, as defined in the intervention effect attribute of the addendum, will have a
direct bearing on the value of the estimand. As a consequence, the estimand, and thus
also the estimate of interest, is becoming more dependent on the characteristics of the
population. These considerations apply not only to T2E but any type of endpoint.
2.2 Variable
When defining an estimand, the attribute variable is intended to summarize the quan-
tities required to address the scientific question. For a T2E endpoint this would be, in
line with Altman and Bland [15]:
• Starting date: Typically, in a clinical trial this is either the date of registration
into a (single-arm or non-randomized) trial or the date of randomisation. For
simplicity, we will generally use “randomisation” to refer to the starting date.
• Event defining the endpoint: As discussed e.g. in Chapter 2 of Klein andMoeschberger
[16], the event of interest may be death, appearance of tumor, development of some
disease, recurrence of a disease, and so forth.
In the simplest case, e.g. when looking at OS, the starting date and event date are
precisely defined up to the exact day. On the other hand, when the event date is
determined through pre-specified assessments, e.g. regular tumor imaging in oncology,
then the resulting T2E might have a density that has peaks around these assessment
dates if one simply assumes that the data is right-censored at the actual assessment date
4
(instead of interval-censored with interval between two consecutive assessment dates).
This manifests through “steps” in the survival curve when nonparametrically estimated
through, e.g., Kaplan-Meier. An example for this pattern is PFS in the CLEOPATRA
trial [17].
The definition of the endpoint might involve more than one timepoint. We discuss
an example from Multiple Sclerosis in Section 5. Interestingly, this also implies that
intercurrent events can not only happen between randomisation and the endpoint, but
also between the initial and final assessment of the endpoint itself.
2.3 Intervention effect
The intervention effect defines how intercurrent events, i.e. potentially treatment-related
clinical events that occur between randomisation and before the endpoint, are reflected
in the scientific question. As a matter of fact, what constitutes an intercurrent event
for a given variable depends on the variable itself and the disease indication, i.e. the
population attribute. A key difficulty when defining the summary measure in Section 2.4
is that an observed intercurrent event typically depends on the treatment received. We
provide a list of intercurrent events in a standard oncology setting in the case study in
Section 7.
In what follows, we discuss the strategies proposed in the addendum (Section A.3.2) to
handle intercurrent events as they apply to a T2E endpoint.
• “Treatment policy”: The value for the variable is used regardless of whether or
not the intercurrent event occurs,
• “Composite”: make the intercurrent event part of a composite endpoint by count-
ing it an event defining the endpoint,
• “Hypothetical”: a scenario is envisaged in which the intercurrent event would not
occur, e.g. because the patient switched treatment,
• “While on treatment”: we are interested in the response to treatment prior to
the occurrence of the intercurrent event, e.g. start of second line treatment in the
absence of observing the endpoint,
• “Principal stratum”: restrict the population of interest to the stratum of patients
in which an intercurrent event would not have happened.
Note that a dedicated strategy for each intercurrent event needs to be defined, implying
that in case of multiple intercurrent events, more than one of the above strategies may
be needed to define a single estimand.
Now, assume our trial objective would be “measuring the time between randomisation
and progressive disease (PD)”. The variable attribute of the corresponding estimand
would then be “time from randomisation until PD” and death would be an intercurrent
event. For a T2E endpoint, the intercurrent event of death can be embedded in the
addendum strategies as follows:
• If we counted death as an event we made the intercurrent event part of a composite,
and we get PFS as the variable attribute of our estimand.
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• Death could be considered an intercurrent event competing with progression. In
order to embed this case into the addendum language, recall the addendum defi-
nition of the “while on treatment strategy”: “...we are interested in the response
to treatment prior to the occurrence of the intercurrent event. If a variable is
measured repeatedly, its values up to the time of the intercurrent event may be
considered to account for the intercurrent event, rather than the value at the same
fixed timepoint for all subjects.” So, for a longitudinal endpoint, which is referred
to in this definition, we would simply impute the value of the variable (e.g. numer-
ical score that defines the variable) at the intercurrent event (when patient dies)
as the value at the fixed timepoint. We propose to fit a competing intercurrent
event for a T2E endpoint in the “while on treatment strategy” of the addendum,
as we are equally interested in the response to treatment prior to either the event
of interest or the competing event. On the estimator level this would mean we
would simply censor at death when performing inference on time-to-progression
(TTP). As discussed in Section 3 one then needs to make sure to align the summary
measure with this censoring strategy.
• If we are willing to entertain the assumption that those who die have the same
momentary risk of an event as those that remain in the risk set, we then estimate
with this the hypothetical estimand “time from randomisation until PD, assuming
that the time until PD of patients who died is imputed using the longer term
outcomes of other patients who survived and remained under observation” [18],
and we retrieve the familiar definition of TTP [19], [20]. The assumption e.g. holds
in case of random censoring, i.e. if the censoring time and T2E are stochastically
independent [21].
So, interestingly, both the hypothetical and the “while on treatment” strategy can be
estimated through censoring at the intercurrent event of death. However, the estimand
the resulting estimators are targeting is different, and this manifests itself in the sum-
mary measure attribute of the estimand. We revisit a few points around censoring and
summary measures in the case of competing risks in Section 3.
As becomes clear, the choice between TTP, a competing risk analysis, and PFS is
ultimately a decision about which estimand to look at, and this estimand should be
inferred from the trial objective. Note that compared with TTP, PFS is generally the
preferred regulatory endpoint [19].
The PFS example can also be used to discuss the general concept of a treatment policy
estimand, where the following considerations apply to any type of endpoint, not just
time-to-event. Treatment policy is defined by encompassing the intercurrent event. The
rationale for doing so is that if the intercurrent event impacts the endpoint, this will be
reflected in the resulting treatment effect, i.e. the causal link is preserved. This boils
down to “ignoring”, or not censoring at, the intercurrent event, and that is often consid-
ered the “analogue” to the “intention-to-treat” (ITT) principle introduced in the original
ICH E9 guideline, although much ambiguity is involved around what is considered to
constitute the ITT principle [22]. We would like to caution against the use of such a
broad strategy when defining a treatment policy estimand. If any intercurrent event,
whether pre-specified in the protocol or not, is ignored and a treatment policy estimand
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is postulated, the implied estimand is difficult to interpret. This is because allowing
any intercurrent event is not really a strategy and causality remains unclear. We thus
recommend that any intercurrent event that is ignored for a treatment policy strategy
should still be pre-specified in the protocol and be systematically collected, somehow
leading to a “protocol-defined treatment policy”. Related, and also not specific to T2E
endpoints, Hernan and Robins address issues that may arise from uncritical reliance on
the intention-to-treat principle in pragmatic trials [23]. They provide guidance on how
per-protocol analyses can be used to overcome these issues.
Finally, if applicable, a principal stratum strategy resolves the problem that the occur-
rence of an intercurrent event is generally associated to treatment. This advantage of the
principal stratum strategy comes at the cost of the difficulty to identify the patients in
each stratum. This membership can typically only be inferred through suitable covari-
ates, unless the intercurrent event is completely unrelated to treatment, but then the
“random censoring” assumption would also be met, making a hypothetical estimand
straightforward to estimate. An example is discussed by Shepherd et al [24] and an
estimator of that estimand is proposed by Chiba [25]. An introduction into principal
stratification and how it allows for causal inference is provided by Rubin [26]. Rubin
discusses the issues that come with intercurrent events using the term “intermediate
outcome variables” for intercurrent events, and the concepts are not just limited to T2E
endpoints. He specifically looks into “truncation by death”, so precisely the scenario we
discuss above.
In general, the choice made for each potential intercurrent event for a T2E endpoint,
i.e. making it part of a composite, treat it as competing, be interested in a hypothetical
world where it would not happen, ignore it, or apply the principal strata strategy,
requires intensive discussions about the actual precise trial objective and the implied
estimand.
We recommend to document these choices and the resulting estimands, as well as the
data analysis strategy, in trial protocols, statistical analysis plans (SAP), and publica-
tions, e.g. in tabular form similar to Table 2 in Bellera et al. [27].
For illustration, we provide an oncology case study in Section 7.
2.4 Summary measure
In this section, we first discuss our view on the connection between statistical hypoth-
esis testing and effect quantification in the estimand context. The addendum specifies
in Section A.1. as part of its scope that it “...presents a structured framework to link
trial objectives to a suitable trial design and tools for estimation and hypothesis test-
ing.” However, in what follows the addendum does not explicitly discuss the connection
between testing and estimation, and the paragraph on the summary measure clearly
focuses on estimation, not testing. This may be because for the endpoint type that
initiated the addendum, continuous data collected over time with intercurrent events,
the statistic used for testing and the effect estimate are closely linked and allow for a
consistent interpretation. Depending on how the population survival functions relate to
each other, this link may break down for the most commonly used methods to analyze
T2E endpoints, namely the logrank test and CPHR: If we have non-proportional haz-
ards, the estimand implied by the estimate based on CPHR depends on the censoring
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distribution, and might thus vary from one trial to the next [28, 29]. Furthermore, since
the logrank test is intimately connected with CPHR, the estimand implied by the lo-
grank test suffers from the same deficiency. We will provide a discussion of these aspects
in Section 4. The potential disconnect between testing and estimation in certain cases
offers two distinct ways of making the summary measure component of the estimand
more specific:
1. Either one insists that testing and estimation are consistent. The implication of
this approach would be that for T2E endpoints, methods such as logrank test and
CPHR would potentially need to be replaced by alternative tests and estimators
that are robust against violation of the PH assumption, see Section 4.
2. Or one allows for a two-stage procedure: In a first stage, a valid hypothesis test is
performed which serves as a gatekeeper. “Valid” always refers to maintaining type
I error. If the null hypothesis under consideration is rejected and the effect estimate
points in the right direction, then the trial is considered a success. The analysis
then goes on in a second stage to quantify the effect by which the experimental
treatment is “better” than the control. This effect quantifier would not necessarily
have to be connected to the test statistic of the gatekeeper test.
Based on our experience with several Health Authorities (HA), once the null hypothesis
has been rejected using a valid hypothesis test, it is possible to choose one or more
summary measures which might differ from the one that corresponds to the performed
hypothesis test, even if the chosen summary measure would not reject its associated null
hypothesis. Akacha et al. [30] briefly discuss this aspect in Section 5.7 as well. So it
appears that at least implicitly, the second approach above is acceptable to HAs.
In what follows, we discuss effect quantifiers for a T2E endpoint that are simple, well-
known, correspond to a clear estimand, and can easily be computed from available
data. A discussion of alternatives to the hazard ratio under more general assumptions
is provided in Section 4.
Recall that in a two-arm RCT with a T2E endpoint, the necessary number of events is
typically determined such that a two-sided logrank test of the null hypothesis
H0 : Scontrol = Sexperimental
has the pre-specified power for an assumed alternative hypothesis, if all assumptions are
met [31]. Here, Si = P (Ti > t) is the survival function in treatment arm i ∈ {control,
treatment}, with Ti the corresponding survival time, a non-negative random variable,
and t ≥ 0. If H0 is rejected using a valid test and the effect estimate points in the right
direction, the trial is considered a success and the effect has to be quantified.
One candidate to use is an estimate of the difference (Sexperimental − Scontrol)(t0) at some
timepoint t0 (“milestone survival”) as our summary measure after passing the gate-
keeper. Further potential effect quantifiers that describe and summarize the observed
data are median or any other quantile difference, or difference in restricted mean sur-
vival time [32], the latter being especially relevant in pharmacoeconomic applications,
see e.g. [33]. Instead of differences, ratios or even odds ratios can be based on Sexperimental
and Scontrol. All these estimands rely on an estimate of the survival function, such as
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Kaplan-Meier, or one based on a parametric assumption. The assumptions for the cho-
sen estimator, e.g. about censoring and the suitability of the parametric model, need
to be checked and any summary measure should be accompanied by a quantification of
uncertainty, most likely a confidence interval. Whether and how some of these estimands
are amenable to a causal interpretation is discussed in [34].
The example discussed in Section 6 allows for an illustration of the interplay between
intercurrent event and summary measure in general. We thus defer the discussion on
this aspect of the summary measure to that section.
3 Censoring
When developing a clinical trial, in line with the recommendations by the National
Research Council [35], the order of what needs to be discussed is
1. trial objective,
2. estimand,
3. study design,
4. data collection and handling strategy,
5. estimator.
As a reviewer pointed out, if an intercurrent event is not terminal, then one may choose
to truncate the T2E variable, i.e. the estimand, at this intercurrent event, and this might
often be referred to as “censoring”. However, we propose to leave the word “censoring”
to activities related to the estimator, and use “truncation” instead for the estimand
definition.
Censoring is thus part of the estimator definition and describes how to handle data that
is only partially observed for the T2E variable, either because an intercurrent event
happened before the event defining the variable or the trial ended.
The event end of trial plays a special role in the context of censoring. Note that with
“end of trial” we imply analysis at any pre-specified clinical cutoff, e.g. also when
performing an interim analysis. This cutoff is typically pre-specified at baseline [36],
which implies that the time until the clinical cutoff date is definitely independent of
the time-to-event, i.e. we have random censoring. Using an estimator based on simple
right-censoring, generally referred to as administrative censoring, is thus uncritical [21].
An estimator involving censoring at an intercurrent can be foreseen for two of the five
strategies described in Section 2.3:
• If the estimand specifies a “while on treatment strategy” we consider the situation
of an event of interest and a competing event. It is important that in this case,
the estimator is aligned with the summary measure attribute of the estimand:
hazard-based inference is unbiased for each event-specific hazard separately when
censoring at the intercurrent event(s), see e.g. Beyersmann et al. [37]. A simple
Kaplan-Meier type estimator for the survival curve of the event of interest that
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simply censors at the competing intercurrent event(s) is biased though [21]. To
get probability statements, one has to look at cumulative incidence functions, or
risk quantifiers based on subdistribution hazards [38]. We refer to Geskus [39] and
Unkel et al. [14] for a discussion of these aspects.
• If the estimand specifies a hypothetical strategy, simple right-censoring at the
intercurrent event provides unbiased estimates if we e.g. assume random censoring,
as discussed in Section 2.3.
Andersen [40] and Allignol et al. [21] discuss the subtle difference between random and
independent censoring. Andersen explains that precise mathematical formulations of
independent censoring may be given and that frequently used models for the generation
of right-censored satisfy these conditions. However, the conditions may be impossible
to verify for actual data. Interpreted within the addendum discussion, this re-iterates
the need for sensitivity analyses when assumptions on censoring mechanisms, and thus
estimators to estimate the above estimands, are specified, as also pointed out by Unkel
et al. [14].
4 Logrank test, Cox proportional hazards regres-
sion, and estimating the estimand
For T2E endpoints, the logrank test is overwhelmingly used as a gatekeeper to test H0.
For the logrank test to be valid, the following assumptions about the data are made:
independent censoring, the survival probabilities are the same for subjects recruited
early and late in the trial, and the events happened at the times specified [41]. While
its power is maximal if the hazard functions corresponding to the assumed survival
curves are indeed proportional, the logrank test maintains type I error, and is thus
valid, also under NPH. This, because under H0 we assume identical survival curves and
the PH assumption does trivially hold. The PH assumption is only used to define the
alternative and thus the nature of the test statistic. All this justifies the important role
of the logrank test as a gatekeeper for testing H0 for a T2E endpoint in a regulatory
context.
However, while the logrank test can be developed as a hypothesis test comparing the
standardized difference between expected and observed number of events, the fact that
it corresponds to the score test in a CPHR, see e.g. Section 3.9 in Collett [42], implies
that the estimand connected to the logrank test is the same as the one for CPHR, i.e.
relies on the PH assumption if we deviate from H0. So, under NPH, it is a priori not
clear to what estimand the logrank test corresponds.
Now, under NPH and if there is no censoring, Xu and O’Quigley [43] derive that the
estimate from a CPHR can still be interpreted as a regression effect suitable averaged
over time, i.e. has an interpretable estimand. However, if there is right-censoring,
already Struthers and Kalbfleisch [44] have shown that the estimand targeted by CPHR
is defined implicitly through an estimating equation that depends on the censoring
distribution. As discussed in Nguyen and Gillen [45], this implies that in the presence
of right censoring, the estimand that is estimated by CPHR under NPH depends on
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the censoring pattern of the actual data, which leads to an estimand that varies with
the censoring distribution. The dependence of the estimand value on the censoring
distribution is nicely illustrated by Nguyen and Gillen ([45], Figure 2). As a consequence,
the estimand targeted by CPHR becomes trial-specific, as it is virtually impossible to
replicate the censoring distribution from one trial to the next, even if only administrative
censoring is present. This, because the censoring distribution at least depends on the
accrual pattern and the trial length, which are typically outside of the trial sponsor’s
control. Or, as Boyd et al. [28] put it, “...the usual unweighted Cox estimator will be
consistent for a parameter that is dependent upon patient accrual and dropout patterns
that bear no relevance to the scientific objectives of a clinical trial.” This quote nicely
relates to the estimand discussion, as the primary goal of the addendum is to align
scientific objective, estimand, and estimator.
As discussed in Section 2.3, even in the absence of intercurrent events, we typically have
to deal with at least administrative censoring in a trial with a T2E endpoint. Xu and
O’Quigley [43] and Boyd and et al. [28] provide estimators of an average regression
effect for the continuous time CPHR model, the latter under more general assumptions
on censoring. Extending the work of Struthers and Kalbfleisch [44], these estimators
target an estimand that is again only implicitly defined. However, Xu and O’Quigley [43]
nicely show that the estimator approximates the population average effect
∫
β(t)d F (t),
where β(t) is the time-varying regression coefficient, and F is the marginal distribution
of the failure times. Nguyen and Gillen [45] provide similar results for a discrete hazard
model. The key properties of these estimators are that they are equal to the one from
CPHR under PH ([43], Section 5), but they are robust against the censoring distribution.
This means they are consistent for the same estimand as CPHR if the PH assumptions
is true, and they estimate a quantity that is independent of the censoring distribution
in case of NPH.
In conclusion, by replacing the logrank test and the estimator based on the CPHR by
e.g. the methods introduced by Xu and O’Quigley [43] or Boyd et al. [28], it would
be possible to remove the conceptual problems discussed above, i.e. one would get a
hypothesis test and effect quantifier that
• have a clear estimand
• which would be (asymptotically) independent of the censoring distribution
independently of the PH assumption.
5 Heterogeneity in T2E endpoint definitions
In this section we focus on heterogeneity of endpoint definitions across studies, and
illustrate the implications of this heterogeneity.
In the terminology of the addendum, estimand heterogeneity for a T2E endpoint pri-
marily affects the interplay between intervention effect and variable, i.e. which clinical
events are considered for one or the other, or ignored, make the endpoint incompletely
observed, or treated as competing. The lack of common definitions for T2E endpoints
has previously been recognized in the literature, see Peto et al. [6] for the earliest account
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to the best of our knowledge, including recommendations how to define and report T2E
endpoints. Still, the review by Altman and Bland [7] finds frequent failure to specify
whether non-cancer deaths were treated as events or censored, or how deaths without
relapse were considered in the definition of the endpoint. They re-iterate the recom-
mendation to give a clear definition of the “time origin, the event of interest and the
circumstances where survival times are censored” for each endpoint considered. More
than another decade later, Mathoulin-Pelissier et al. still found that about half of the
reviewed articles published in major clinical journals failed to provide a clear definition
of the T2E endpoint, and 68% reported insufficient information on the survival analysis
[8].
Bellera et al. state that “Most of these T2E endpoints currently lack standardised
definition enabling a cross comparison of results from different clinical trials” [5], clearly
pointing to the need of a discussion of estimands also in this context, although the
authors of the latter paper do not use the term. Even for a binary endpoint, Kahan
and Jairath [46] also find marked differences in estimated odds ratios, depending on
endpoint definition.
An example illustrating the lack of a clear endpoint definition is discussed by Birgisson
et al. [47]. For colorectal cancer, these authors find that the inclusion of second primary
cancer as an event in the definition of DFS relevantly alters effect estimates. They
recommend that researchers and journals must clearly define T2E endpoints in all trial
protocols and published manuscripts. A similar analysis has been performed for colon
cancer [48].
DFS is also the primary end point for many large adjuvant breast cancer trials. The
results of such trials, if positive, will likely change clinical practice, refer to Minckwitz
et al. [49] for a recent example. Historically, which of the five addendum strategies is
applied to a given clinical event has been inconsistent. The typical definition involved
local, regional, and distant recurrence of the tumor, as well as death as events for the
variable, DFS. Often inconsistently handled were
• initiation of treatment for contralateral breast cancer,
• second primary cancers, further depending on whether they were contralateral or
nonbreast,
• and death not due to breast cancer.
Hudis et al. ([50], Table 1) gives an overview and the paper provides recommendations
reached by an expert group. Building on this, the DATECAN initiative (see below, [51])
applied a formal international consensus method, to increase the use and acceptability in
current practice of common definitions. This illustrates that work is still necessary and
is being done to align the definition of the variable attribute in the estimand context. We
hope that with the addendum this alignment will also carry over to the other estimand
attributes.
The aim of the Definition for the Assessment of Time-to-event Endpoints in CANcer
trials (DATECAN) initiative is to provide recommendations for standardised definitions
of T2E endpoints [5] not only for breast but for many cancer indications: those for
pancreatic [52], sarcomas and gastrointestinal stromal [27], breast [51], and renal [53]
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tumors have been published so far. Note that all these efforts are currently made without
explicit referencing to the estimand framework in general, or the framework put forward
by the addendum. The consensus defines how intercurrent events and the variable are
recommended to be handled, but the other estimand attributes, population and summary
measure, are left open.
The Steering Committee of the DATECAN project considered defining censoring rules
to be a statistical rather than a clinical question [53]. As a result, censoring rules were
not discussed during the DATECAN consensus process. Disentangling the estimand
from the estimator is in line with our recommendation in Section 3, i.e. the clinical
question is the definition of the estimand and it remains then a statistical challenge to
estimate the targeted quantity. However, from the description in Bellera et al. [5], it
remains unclear how much the decisions on the actual estimand made in the DATECAN
initiative are actually derived from a clearly defined scientific objective.
Another initiative with the goal of improving reporting of clinical trials is the CON-
solidated Standards Of Reporting Trials (CONSORT) statement [54]. Although CON-
SORT is aimed at structuring reporting of RCTs in general, many of the items on the
CONSORT checklist aim at improving the definition and description of trial objectives,
population, endpoints, and outcomes and estimation. So, the CONSORT statement
actually covers a substantial portion of the four attributes that make up an estimand
in the addendum, for any type of endpoint, not only time-to-event. The addendum can
thus be seen as detailing the aspects pertaining to these CONSORT items further, and
connecting them more directly to the trial objective.
Acknowledging the current state of heterogeneity in the definition of T2E endpoints, in
what follows we would like to point out what this potentially implies in RCTs.
As discussed in Section 2.4, whether an RCT is considered a “success” generally de-
pends on rejection or non-rejection of the considered null hypothesis. So the question
of “statistical significance” carries substantial weight, and pronouncedly so for trials
potentially leading to regulatory approval. Montalban et al. [3] provide an example
for Multiple Sclerosis: The primary variable was time-to-initial disability progression
(time-to-IDP), which had to be confirmed 12 weeks after IDP, and the associated lo-
grank test was statistically significant. However, since not all patients come back 12
weeks after their initial assessment to have their progression confirmed, for the primary
analysis it was assumed that all these patients progressed (Table S10 in [3]). An alterna-
tive definition of the endpoint, imputing half of the patients randomly as event and the
other half as censored, was analyzed as part of a range of sensitivity analyses, yielding
a non-significant logrank test. This example also provides a case study of a variable
attribute that is assessed at different timepoints, implying that intercurrent events can
also happen within the variable attribute itself.
Similarly, van Cutsem et al. discuss colon cancer, with endpoint DFS in the PETACC-3
trial [55]. The primary definition in the trial protocol counted second primary cancer
other than colon as an event, and with this definition, the trial is reported to be “non-
significant” [55]. However, the evaluation of relapse-free survival (RFS) as defined in
the PETACC-3 protocol (which corresponds to the definition of DFS in the MOSAIC
trial, [56]!) showed a p-value of 0.02 and was called “statistically significant” [55].
Not surprisingly, estimates of event-free probabilities at 3 and 5 years are different
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for different variable definitions as well [57], see Bellera et al. for further details [5].
Note that the trial objective of “improving DFS” is not nearly specific enough to imply
unambiguous definitions.
Meta-analyses will not provide reliable summary estimates if studies with different def-
initions of variables and/or intercurrent events are being compared [47].
“Dynamic borrowing” of historical data has gained some popularity recently [58], but
that also raises the question of “compatibility” of the historical data used in these kind
of trials, not only from a statistical perspective but also in terms of estimand definition.
In an analysis combining data from several trials in colon cancer to assess surrogacy
of DFS for OS after various times of follow-up [59], among them PETACC-3 [57] and
MOSAIC [56] for which DFS definition was different in terms of handling second tumors
[55], the DFS definition given is: “DFS was defined as the time from randomisation to
the first event of either disease recurrence or death due to any cause.” No discussion
of how second tumors were handled can be found in this surrogacy assessment, thus
the reader is left uncertain which estimand was actually targeted by the analysis. The
authors further found that the previously established surrogacy of DFS after 2- and
3-year median follow-up for OS in Sargent et al. [60] was now modest to poor in this
follow-up analysis based on six new trials not included in the previous analysis. The
authors attribute this reduction in the amount of surrogacy based on the same amount
of follow-up (2 and 3 years for DFS, 5 and 6 years for OS) as in Sargent et al. [60]
to generally longer DFS and OS achieved in colon cancer over time through improved
therapy and combinations. One can only speculate on the possible contribution of
heterogeneity in DFS variable definition to the lack of surrogacy in this case.
Effect estimates depending on the definition of an estimand may also complicate plan-
ning of future trials, as assumptions for the control arm in a new trial are often based
on estimates of the treatment arm in previous trials.
To summarize, unprecise definitions may impact statistical significance, effect estimates,
feasibility of meta-analysis, dynamic borrowing, and surrogacy assessments, and can bias
assumptions for planning of future trials.
The addendum (Section A.4) emphasizes the need for construction of a suitable estimand
when summarising data across trials. This means that to allow cross-trial summaries,
the estimand in each single trial needs to be described in sufficient detail, to enable an
assessment of which studies to combine and to quantify the “estimand heterogeneity”.
6 Analysis strategy for given intercurrent event de-
pending on indication
In this section, we illustrate how the same intercurrent event, initiation of new therapy
in lymphoma in the absence of PD, might need to be considered differently for the same
T2E endpoint, depending on the disease indication considered.
PFS is a commonly accepted regulatory endpoint in Non-Hodgkin Lymphoma (NHL), for
both, the indolent (follicular, FL) and aggressive (diffuse large B-cell, DLBCL) subtype
[61]. FL is incurable and DLBCL is potentially curable, but patients failing to achieve a
complete remission (CR) after initial induction treatment have a dismal outcome. This
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means that physicians might treat such a DLBCL patient with a new anti-lymphoma
therapy (NALT) of their choice already prior to formal imaging-based determination of
progression to the first-line therapy in case of non-CR (i.e. if they have either stable
disease or partial response), in order to maximize the odds to still get the patient to
CR. So, NALT can be considered a potential intercurrent event for the endpoint of PFS.
For FL, in line with regulatory guidelines [19], PFS is generally defined as time from
randomisation to the earlier of disease progression or death [1], and NALT is ignored for
PFS, implying a treatment-policy estimand. Ideally, those NALTs that are allowed to
be administered within the trial are protocol-specified, see the discussion in Section 2.3.
In DLBCL, PFS is often defined as for FL (e.g. in the GOYA trial, [62]), although the
lymphoma-specific harmonization effort by Cheson et al. [61] indicates that “...in studies
in which failure to respond without progression is considered an indication for another
therapy, such patients should be censored at that point for the progression analysis.”
The estimand corresponding to the definition of the variable PFS in this case would be
a hypothetical one. The censoring rule implies that for patients who fail to respond,
their PFS is imputed (terminology used by Fleming et al., [18]) based on patients that
did respond, but had longer follow-up. Interestingly, in another highly cited paper it
is recommended that “...patients should not be censored at the time other treatments
are initiated when analyzing the PFS end point...” [18]. Here, the interest focuses on
a treatment-policy estimand strategy. Given the conflicting recommendations given by
regulatory guidelines and key opinion leaders, how should a researcher designing a trial
using PFS as the primary endpoint proceed to define this endpoint? In the framework
of estimands for a T2E endpoint outlined in Section 2, the definition of the variable
that defines PFS appears unambiguously accepted: starting date is randomisation and
the event defining the endpoint is the earlier of PD and death. To define the potential
estimand we identify two potential intercurrent events:
• Failure to respond to induction therapy, but no PD (IC1).
• Initiation of NALT, but no PD (IC2).
Note that it is not entirely clear from the statement in Cheson et al. [61] whether these
authors really think of two different intercurrent events when they write “...failure to
respond” or whether they implicitly assume IC1 = IC2. In any case, to be as precise
as possible, we consider both these events separately in our discussion, as it is not
entirely implausible that a patient with partial response only at end of induction will
not immediately receive NALT. A number of estimands that could be defined by treating
IC1 and IC2 are summarized in Table 1. For the estimation of the estimands in Table 1
we propose to administratively censor at the last non-PD tumor assessment for the
clinical cutoff, and also to censor at the intercurrent event whenever we consider a
hypothetical estimand.
As for the summary measure, the choice depends on which of the two approaches de-
scribed in Section 2.4 is preferred and whether the PH assumption is sensible in this
indication. The preferred approach will likely evolve after the addendum has been fi-
nalized and substantive knowledge of the DLBCL indication is needed to decide on the
plausibility of the PH assumption. Whether the PH assumption seems appropriate or
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not depends on the choices made for the other three estimand attributes, most specifi-
cally the intervention effect. For simplicity, in Table 1 we make the PH assumption.
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Estimand Population Variable Intervention effect Summary measure Comment
Option 1 DLBCL pa-
tients, defined
by list of in-
and exclusion
criteria
PFS NALT: treatment policy
Failure to respond: treatment policy
Death: composite
logrank test and haz-
ard ratio
Corresponds to definition in Flem-
ing et al. [18]. Used in large RCT
[62].
Option 2 as Option 1 as Option 1 NALT: hypothetical
Failure to respond: treatment policy
Death: composite
as Option 1
Option 3 as Option 1 as Option 1 NALT: treatment policy
Failure to respond: hypothetical
Death: composite
as Option 1 Corresponds to definition in Cheson
et al. [61].
Option 4 as Option 1 as Option 1 NALT: hypothetical
Failure to respond: hypothetical
Death: composite
as Option 1
Option 5
(Event-free
survival,
EFS)
as Option 1 PFS be-
comes
EFS
NALT: composite
Failure to respond: hypothetical
Death: composite
as Option 1 Similar to PFS, may be useful in
evaluation of highly toxic therapies,
only acceptable for HAs if NALT is
supported by some “objective” eval-
uation of treatment failure in the ab-
sence of PD. Used as part of a sur-
rogacy assessment [63].
Table 1: Potential PFS estimands for DLBCL, depending on how intercurrent events are considered. Estimand strategies according
to the addendum are emphasized in bold.
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Not all estimands in Table 1 may be of practical interest. Furthermore, Options 2-5
all contain at least one intercurrent event for which a hypothetical estimand strategy is
proposed. For an estimator based on simple censoring at IC1 and/or IC2 to be unbiased,
assumptions on the censoring mechanism, e.g. random or independent censoring, have
to be made, see Section 3. The need to adjust for the potential dependence of the effect
estimate on the intercurrent events via methods that can deal with, what they call,
“informative censoring” led Fleming et al. to actually advocate Option 1 in this context
[18]. However, the estimand framework in the addendum might potentially reverse
that thinking: ideally, one first determines a trial objective which is then translated in
estimand strategies to handle the intercurrent events. The last step is then to define
an estimation strategy that is able to estimate the selected estimand, potentially at the
price of added assumptions or the need for advanced methodology. In any case, we find
that depending on how we consider the intercurrent events IC1 and IC2, we get different
estimands for an endpoint that is commonly called “PFS”, and with Option 5 even one
that is considered a different endpoint. EFS has lately been considered an endpoint for
DLBCL as well [63].
For FL, the situation is different, as in this indolent disease, failure to achieve response
after induction therapy does not necessarily trigger NALT. Rather, physicians indeed
wait with inducing NALT until the patient experiences progression, so that PFS as an
endpoint is indeed more reflective of the actual clinical treatment of this disease.
The comparison between DLBCL and FL illustrates that even for two quite related
diseases, for which often the same treatment is applied, defining a relevant estimand
might not be straightforward and needs careful assessment on what actually a therapy
under study should achieve, and what the precise trial objective is. Irrespective of
which estimand is chosen, we strongly recommend that trial developers try to identify all
potential intercurrent events upfront, and clearly indicate for the finally chosen estimand
and each intercurrent event whether the latter is considered within a treatment policy, in
the context of a hypothetical estimand, as part of a composite endpoint, or as competing.
We recommend to make that transparent in a table similar to Table 1.
To conclude this section, and to finish the discussion on summary measure in Section 2.4,
we would like to comment on the interplay between intervention effect and summary
measure. The above debate on how to treat the intercurrent event “initiation of NALT”
for PFS was settled by a general recommendation [18] to use a “treatment policy”
strategy for this intercurrent event. One, if not the major, justification to favour the
treatment policy estimand is to avoid having to censor at NALT, i.e. the insight that
a hypothetical estimand would potentially be difficult to estimate. With this approach,
the question of NALT is dealt with in the definition of the intervention effect. Now,
instead of changing the estimand from hypothetical to treatment policy to avoid having
to deal with assumptions for censoring when defining the estimator, one could equally
well consider adjusting the summary measure, e.g. by applying inverse probability of
censoring weighting (IPCW), see e.g. [64] or [65]. This method allows, again under
some but now different assumptions (no unmeasured confounders, [66]), to estimate the
survival function and consequently the treatment effect if no patient had started NALT,
so again a hypothetical estimand strategy. Alternatively, an estimand defined through a
rank-preserving structural failure time model (RPSFT, [67]) assesses the counterfactual
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event time of a patient, i.e. again the T2E if no NALT were received [65]. This can
equally well be considered a hypothetical estimand. These considerations illustrate that
various estimators can be defined for the same estimand. Interestingly, methodology
to estimate a hypothetical estimand such as IPCW and RPSFT, have been developed
long ago in the context of causal inference and successfully applied in many instances,
especially in epidemiological applications. We anticipate that the addendum provides
a framework and a common language that will facilitate and foster implementation
of such advanced estimation methodology, because these are made necessary by the
trial objective and the estimand derived from it. Furthermore, it is important to note
that the “no unmeasured confounder” assumption for IPCW requires that (as much
as possible) data on prognostic factors that explain initiation of NALT needs to be
collected, by pre-specifying these factors in the data collection and handling strategy,
according to the list in the National Research Council’s report [35], see Section 2.3.
Having a hypothetical estimand defined upfront will shift focus of a sponsor to collecting
necessary information during the trial, another advantage of the estimand framework,
as outlined in the addendum (Section A.1). Already Watkins et al. [65] emphasize
that “...Often, only limited data are collected after the patient experiences the primary
regulatory endpoint, which can mean important time-varying confounders are missed
or that switch dates or time on/off treatment cannot be accurately defined. Careful
upfront planning is required.” We expect such planning to become more standard after
the addendum is in place.
7 Case study: the GALLIUM trial
The GALLIUM trial [1] assessed whether replacing the anti-CD20 antibody rituximab
by a second generation anti-CD20 antibody, obinutuzumab, increases PFS. The trial was
unblinded after it crossed the pre-specified significance level at a pre-planned efficacy
interim analysis and was fully analyzed. The trial randomized 1202 FL patients and
an additional 195 marginal-zone lymphoma (MZL) patients. The latter cohort can be
considered a Phase 2 trial within the same protocol, whereas the first constituted the
primary analysis population. Due to regional heterogeneity in standard of care, trial sites
had to select one of three chemotherapy backbone therapies. Chemotherapy as well as
Follicular Lymphoma International Prognostic Index (FLIPI1, [68]), a prognostic score
used in FL, were used as stratification factors in the analysis.
Table 2 provides details on the primary analysis and a list of all sensitivity analyses (with
term “sensitivity” referring to the pre-addendum meaning in the GALLIUM protocol)
reported in the clinical study report (CSR) for the primary endpoint, PFS as assessed by
the investigator (Inv-PFS). We provide columns for each of the four estimand attributes
introduced in the addendum. As almost all the analyses in Table 2, and also Table 3,
are targeting different estimands than the primary by varying at least one of the four
attributes, in the post-addendum language these are in fact all supplementary analyses.
The only exceptions are variations of the primary analysis by considering an unstratified
instead of a stratified logrank test and a re-randomisation test. These truly vary the
underlying assumptions of the primary estimand. We have still added these variations
to the summary measure column for simplicity, but they target the primary estimand,
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as indicated in the first column of the tables.
Depending on the endpoint, the intercurrent events we consider are death, NALT, pro-
gression, withdrawal, drop-out, discontinuation of trial treatment, and missed scheduled
response assessment. While all these were systematically collected on the electronic case
report form, the list of “allowed” NALTs was not pre-specified in the protocol, because
NALT was not foreseen prior to observing the actual endpoint, PFS. So, as discussed in
Section 2.3, one can argue that it is not entirely clear what precise objective, or effect
quantification, corresponds to a treatment policy estimand strategy applied to the in-
tercurrent event NALT. However, for illustrative purposes we ignore this aspect in our
case study, i.e. if in the tables below we discuss ignoring NALT for an estimand we call
this treatment policy.
Table 3 then continues to describe all the T2E endpoints listed on https://clinicaltrials.gov/ct2/show/NCT01332968.
In the original protocol, SAP, and CSR, these analyses were provided as a long list and
have been selected based on substantive considerations, regulatory guidelines [19], expe-
riences from previous trials, and feedback from HAs on studies in the same development
program. In the estimand framework, these are supplementary analyses. We would
like to emphasize that this is an after-the-fact exercise with the aim of learning how to
structure an estimand and analysis plan in the future based on the addendum.
Note that the primary and some of the secondary T2E endpoints were evaluated in
the FL and overall, i.e. FL + MZL, population. For simplicity, we focus on the FL
population only in both Tables. Adding the overall population to the lists would be a
simple variation of the population attribute.
The estimand definitions in Table 2 are complemented by the following data analysis
strategy:
• Clinical cutoff for PFS: administratively censor at the last non-PD tumor assess-
ment.
• Primary: PDs were collected after NALT, so the treatment policy strategy could
be applied. However, data on PD was not routinely collected after drop-out and
withdrawal. As a consequence, estimation was based on censoring at these inter-
current events, implying a hypothetical estimand.
• Supplementary 1: Withdrawals prior to PD: consider event at next scheduled
disease assessment date in obinutuzumab arm, censored at last disease assessment
for rituximab.
• Supplementary 2: Missed assessment prior to PD or clinical cutoff date: considered
event at day after last response assessment.
• Supplementary 3: NALT prior to PD: censor at NALT.
• Supplementary 4: Discontinuation of trial treatment for other reasons than PD/death:
consider event at time of discontinuation.
• Supplementary 5: Death ≥ 6 months after last non-PD response assessment: cen-
sored at last available response assessment.
The assumptions imposed when censoring at an intercurrent event are discussed in
Sections 3 and 6.
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Analysis Population Variable Intervention effect Summary measure Rationale
Primary FL patients, de-
fined by list of
in- and exclu-
sion criteria
Inv-PFS NALT: treatment policy
Drop-out, withdrawal: hypothetical
Death: composite
unadjusted hazard
ratio and logrank
test, stratified by
chemotherapy and
FLIPI1
Composite: interest would be in
time-to-progression, but we make
“death” part of a composite.
“Primary” as primary IRC-PFS as primary as primary
Sensitivity 1 as primary as primary as primary unadjusted hazard ra-
tio and logrank test,
unstratified
Sensitivity 2 as primary as primary as primary unadjusted hazard
ratio and logrank
test, stratified, using
re-randomisation
Assesses sensitivity of stratified log-
rank test to dynamic randomisation
procedure, see e.g. [69].
Supplementary 1 as primary as primary Withdrawals prior to PD: composite for
obinutuzumab, hypothetical for rituximab
as primary Assess impact of loss to follow-up.
Supplementary 2 as primary as primary Missed assessment prior to PD or clinical cut-
off: composite
as primary Assess impact of missed assess-
ments.
Supplementary 3 as primary as primary NALT prior to PD: hypothetical as primary Assess potential confounding of the
treatment effect estimates by subse-
quent therapy. See also Section 6.
Supplementary 4 as primary as primary Discontinuation of trial treatment for other
reasons than PD/death: composite
as primary
Supplementary 5 as primary as primary Death ≥ 6 months after last non-PD response
assessment: hypothetical
as primary
Table 2: List of original sensitivity analyses from GALLIUM protocol. “IRC-PFS” stands for PFS as assessed by independent
review committee, see the discussion below. The column Analysis uses the post-addendum terms. Estimand strategies according
to the addendum are emphasized in bold.
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The primary analysis yielded an estimated hazard ratio of 0.66, with p-value 0.0012 and
95% confidence interval from 0.51 to 0.85 [1]. All but Supplementary Analysis 1 were
sufficiently consistent with this result.
Assembling Table 2 provided the following insights that may be helpful in designing
future studies or analysis plans:
• It is not entirely obvious how to position IRC-PFS. The primary endpoint of the
trial was Inv-PFS, meaning that the timing of the clinical cutoffs for interim anal-
yses was based on the number of events for Inv-PFS, and the p-value for this
endpoint was primarily considered by the independent data monitoring commit-
tee (iDMC) when making their recommendation to either stop or continue the
trial at any interim analysis. However, the iDMC charter also asked the iDMC
to ascertain that point estimates for Inv- and IRC-PFS were “consistent”. Fur-
thermore, the protocol stated that Although the primary efficacy endpoint is the
investigator-assessed PFS, PFS based on IRC assessments will also be analyzed to
support the primary analysis. In the United States, IRC-assessed PFS will be the
basis for regulatory decisions. For that purpose, all the analyses in Table 2 had
been repeated for IRC-PFS and, given their importance for regulatory purposes
and since we only alter one aspect of the primary estimand (assessment method
for PD), we consider these still sensitivity analyses for Inv-PFS. However, one
could argue that these should rather be deemed supplementary in post-addendum
language, as they could be considered targeting an alternative estimand.
• Each sensitivity analysis only modifies one aspect of the primary analysis at a
time, in line with the recommendation in the addendum.
• For Supplementary Analysis 1, a different strategy for the intercurrent event is used
depending on which arm the patient who withdrew was randomized to, so this can
be considered a “worst case” approach. In hindsight, the scientific objective, the
implied estimand, and the estimated treatment effect based on it is thus difficult
to interpret, to say the least.
• For the hypothetical estimand in Supplementary Analysis 3, the analysis strategy
specifies censoring at initiation of NALT, as in Section 6. We thus estimate PFS
assuming that those patients who received NALT are comparable to those that
did not need NALT. As discussed in Section 3, if the corresponding effect estimate
should be unbiased we need to make e.g. the assumption of random censoring,
but based on the discussion by Fleming et al. [18], this assumption is unlikely to
hold. As discussed in Section 6, IPCW or RPSFT would be (complex) options to
estimate a hypothetical estimand.
• In Section 2.4 we discuss that one could argue to split the summary measure in
two separate attributes, one for the hypothesis test and one for the effect estimate.
In this context it is noteworthy that Sensitivity Analysis 2 indeed only varies the
hypothesis test, but not the effect estimate.
• Finally, the choice of the summary measures implies that PH was assumed for
all the estimands in Table 2, and also Table 3. For the primary endpoint, Inv-
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PFS, this assumption was based on results of the predecessor trial PRIMA [70].
The treatment arm from PRIMA became part of the control arm of GALLIUM,
and estimates of the survival function of the treatment arm in PRIMA revealed
a remarkably constant hazard of an Inv-PFS event over time, a feature regularly
observed in FL. The trial team thus assumed the same shape for the hazard func-
tion in the experimental arm in GALLIUM, leading to the PH assumption. And
in fact, the analysis of GALLIUM indeed showed quite constant estimated hazard
functions and thus the PH assumption seemed justified also in hindsight. Inter-
estingly, the average regression effect as proposed by Xu and O’Quigley [43] was
estimated to be 0.68 (computed using the R [71] package coxphw [72]), so quite
close to the estimated primary analysis hazard ratio.
Strictly speaking, the above rationale justifying the PH assumption based on an
earlier trial exclusively applies to Inv-PFS in GALLIUM. Similar considerations
for all the other analyses in Table 2 and 3 had not been made at the time.
The GALLIUM trial also reported a set of results on secondary endpoints [1]. These are
listed in Table 3 and, in post-addendum language, these would be “supplementary”. It
is remarkable that all these endpoints, i.e. OS, Time to NALT (TTNALT), EFS, DFS,
and duration of response (DOR) are basically received by varying handling of clinical
events for the variable and intervention effect, as well as the population attribute for
DFS and DOR. The analysis strategies for the estimands in Table 3 are the same as for
Table 2 and in addition:
• Clinical cutoff for OS and TTNALT: administratively censor at date last known
alive.
• Supplementary 7: The protocol specified that after PD, patients were to be fol-
lowed up for NALT and death, allowing to use a treatment policy strategy for PD
for TTNALT.
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Analysis Population Variable Intervention effect Summary measure Rationale
Primary FL patients, de-
fined by list of
in- and exclu-
sion criteria
Inv-PFS NALT: treatment policy
Drop-out, withdrawal: hypotheti-
cal
Death: composite
unadjusted hazard
ratio and logrank
test, stratified by
chemotherapy and
FLIPI1
Composite: interest would be in
time-to-progression, but we make
“death” part of a composite.
Supplementary 6
Overall survival
as primary OS PD, NALT: treatment policy
Drop-out, withdrawal: hypotheti-
cal
as primary
Supplementary 7
Time to NALT
as primary TTNALT, time
from randomisa-
tion to death or
NALT
PD: treatment policy
Drop-out, withdrawal: hypotheti-
cal
NALT, death: made part of a com-
posite
as primary
Supplementary 8
Event-free survival
as primary EFS, time from
randomisation
to Inv-PFS
event or NALT
Drop-out, withdrawal: hypotheti-
cal
NALT, death: made part of a com-
posite
as primary
Supplementary 9
Disease-free sur-
vival
Patients with
CR prior to
NALT
DFS, time from
first occurrence
of CR to Inv-
PFS event
as primary unadjusted hazard
ratio, stratified by
chemotherapy and
FLIPI1
Non-randomized comparison be-
tween arms, no hypothesis test
performed.
Supplementary 10
Duration of re-
sponse
Patients with
PR or CR prior
to NALT
DOR, time from
first occurrence
of PR or CR to
Inv-PFS event
as primary unadjusted hazard
ratio, stratified by
chemotherapy and
FLIPI1
Non-randomized comparison be-
tween arms, no hypothesis test
performed.
Table 3: List of supplementary analyses from GALLIUM protocol. “PR” stands for “partial response”. The column Analysis uses
the post-addendum terms. Estimand strategies according to the addendum are emphasized in bold.
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8 Discussion
In this paper, we have outlined an estimand framework for a T2E endpoint and dis-
cussed all four estimand attributes defined in the addendum as they apply to a T2E
endpoint. We illustrate that these attributes cannot be seen independently, but have
to be considered inter-related. Intercurrent events often make measurements of a T2E
endpoint incomplete, or even impossible to observe in the case of an intercurrent event of
death. Depending on the targeted estimand, various approaches can be used to estimate
it. For a hypothetical estimand, simple censoring at the intercurrent event may often
yield a potential estimator, but at the price of the strong assumption that the endpoint
for those patients experiencing the intercurrent event can be “imputed” using data from
patients with longer follow-up, but not experiencing the intercurrent event. Alterna-
tively, methods developed in the causal inference literature can be used to estimate a
hypothetical estimand, making alternative assumptions and necessitating data collec-
tion on factors that are prognostic and predict the intercurrent event, e.g. a treatment
switch [73].
As summary measures, the logrank test and the hazard ratio based on the CPHR are
overwhelmingly used today in the routine analysis of trials with T2E endpoints. How-
ever, both these methods are intimately connected to the PH assumption. While the
PH assumption may often be made based on previous or external knowledge, as e.g. in
GALLIUM in Section 7, there are indications where it is clear that it generally does not
apply, e.g. immuno-oncology [74]. Still, trials are often powered based on the logrank
test and the pre-specified effect quantifier is based on CPHR. This asks for a choice
between the two potential ways of moving forward in the context of the addendum as
outlined in Section 2.3.
• Making testing and estimation consistent even under NPH would methodologically
be possible, using e.g. one of the estimators discussed in Section 4. The trade-
off would be a major logistical and educational effort for all parties involved, i.e.
rewriting of programming and reporting templates and education of statisticians,
clinicians, HAs, and the broader scientific community on the application and inter-
pretation of these methods. Also, if, as an example, the average regression effect
approach by Xu and O’Quigley [43] would be adopted, methodology would first
have to be developed e.g. for sample size computation, sequential monitoring of a
trial, estimation of this average effect from interval censored data, etc.
• The other option to move forward would be the gatekeeper approach, which is at
least informally accepted by HAs today.
If this second approach remains valid moving forward, it would be crucial for trial
sponsors to understand:
• Even if the hypothesis test can be different from the effect quantifier - is validity of
the chosen hypothesis test enough to justify its application, or does the hypothesis
test still need to refer to a clearly defined estimand? This would make the use of
the logrank test questionable under NPH.
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• What are the criteria that will make HAs accept an effect quantifier? As suggested
by a reviewer, could it be an option to base the hypothesis test on an analysis
method that makes a set of plausible but minimal assumptions, but then use one
or more effect quantifiers in the package insert making different and/or stronger
assumptions, e.g. proportional hazards or even parametric?
A discussion of these aspects, specifically the role and interplay of testing and estimation,
in the ICH E9 final addendum or general guidance by HAs on these aspects would
certainly help sponsors to set up RCTs with T2E endpoints in the future, especially
when NPH is anticipated.
Irrespective of which approach is favoured, a general comment on the causal interpreta-
tion of T2E data and hazard ratios is in order. As discussed by Akacha [75], while the
addendum is not explicitly mentioning the word “causal”, reference to “causal think-
ing” is made implicitly via referencing potential outcomes (Section A.3.1) and adoption
of the principal stratum strategy. However, as e.g. Hernan [76] and Aalen et al. [29]
point out, the use of the hazard ratio for causal inference is not straightforward, even
in the ideal situation of PH and absence of unmeasured confounding and measurement
error. Furthermore, as discussed by Hernan ([36], Fine point 17.1), truncation of a T2E
variable by competing events raises logical questions about the meaning of a causal es-
timand, and these issues cannot be bypassed by statistical techniques. So, even when
perfectly adopting the addendum framework for T2E endpoints in the future and PH
being fulfilled, validity of causal conclusions for a T2E endpoint might remain unclear,
even in an RCT, and needs further research. We would also welcome if the addendum
in its final form could be more clear on whether estimands have to be constructed in
a way that they allow for causal statements, or alternatively, if the addendum can be
interpreted more in the sense of an “operational guidance” of how to set up RCTs well
and transparently.
Interestingly, as discussed by Aalen et al. [29], accelerated failure time models could po-
tentially provide both, effect estimates that are robust against the censoring distribution
and allow for a causal interpretation.
We have discussed the current heterogeneity in variable definitions and the DATECAN
initiative that aims at unifying these definitions in many indications in oncology. On
top of that, harmonization efforts are underway for response definitions, e.g. extending
the Response Evaluation Criteria In Solid Tumours (RECIST) guideline to testing drug
agents in immunotherapy [77]. We are definitively supportive of all these efforts and hope
that these will be extended to other disease areas as well. However, with a precisely
defined endpoint and strategy how to handle intercurrent events, only part of what
constitutes an estimand according to the addendum is specified. We believe that the
estimand framework will further help to align trial objectives and quantification and
interpretation of effects. In addition, having the estimand discussion within teams at
trial onset will help to define the data collection strategy. If a hypothetical estimand
is targeted e.g. for OS, data collection strategy becomes especially important: data
on prognostic factors for experiencing an intercurrent event, e.g initiation of NALT or
a switch from control to treatment arm, needs to collected. Hudis et al. provide an
illustrative discussion on these aspects in the penultimate paragraph of their paper [50].
One aspect is important to note in this context: for potentially lethal diseases like many
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cancers, patients remain under treatment also after progression, often even within the
initial trial protocol, so that follow-up for OS is feasible. Such comprehensive follow-up
for OS might be more difficult to achieve in other indications, e.g. Alzheimer’s disease.
Experience shows that if patients stop treatment, due to the high burden a visit to the
hospital with all the trial assessments is for the patient and caretakers, the odds that
patients completely drop-out of the trial after stopping treatment are higher than in
many oncology indications.
We illustrate our points with two case studies from oncology, and we show that familiar
endpoints such as PFS, TTP, or EFS can be simply interpreted as different estimands.
Strict compliance to the estimand methodology outlined in the addendum is desirable
moving forward. However, as remarked by a reviewer, this may increase costs, e.g.
because of power loss when using the treatment policy strategy for an intercurrent
event or diluting endpoints when using the composite strategy.
Regulatory guidelines, e.g. the FDA Guidance for Industry: Clinical Trail Endpoints
the Approval of Cancer Drugs and Biologics [19], specify definitions of endpoints such as
PFS or TTP, and also outline potential sensitivity analyses. This guidance is reflected
in the list of analysis for GALLIUM in Tables 2 and 3. However, the guidance currently
does neither discuss the assumptions that are (implicitly) made on censoring nor are
estimands specified from which the proposed analyses, or estimators, are derived. We
anticipate that regulatory guidelines will have to updated to reflect the changes brought
to ICH E9 by the addendum.
Based on our experience and working on the tables in Section 7, and similar to the
recommendations by Hernan and Robins [23] in the context of pragmatic trials, we
recommend that when defining an estimand for a trial with a T2E endpoint, the sponsor
should
• involve all relevant stakeholders of the trial, i.e. statisticians, clinicians, inter-
nal regulatory colleagues, health authorities, payer organizations if the trial is
industry-sponsored, and maybe even patients,
• identify all endpoint-defining and potential intercurrent events,
• define for each intercurrent event the estimand strategy to be applied, ideally by
inferring this strategy from a precisely formulated trial objective,
• tabulate all these events and determine for each of them an estimand strategy,
• and finally apply or develop methodology that can estimate the chosen estimand,
with a precise definition of the estimator and a description and discussion of the
assumptions made, e.g. with respect to censoring.
By doing so, the sponsor should make sure to take into account aspects specific to the
disease under study and make an effort to match the definition with either guidelines in
the field, such as DATECAN, CONSORT, or RECIST, or other clinical trials. This will
facilitate discussions on regulatory approval, allow for easier comparison of trials now
and in the future, and allow the use of trial data as historical controls, in meta-analyses,
or surrogacy assessments.
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